Biocon falls 8% on heavy volumes

In past one month, the stock was down 21% against 2% decline in Sensex.

Biocon has dipped 8% to Rs 321 on BSE in intra-day trade on the back of heavy volumes on reports of withdrawal of Trastuzumab application.

On status of the European Medicines Agency (EMA) Dossiers, Biocon said that the European regulatory authorities had informed the company the need for a re-inspection of drug facility for Trastuzumab and Pegfilgrastim products.

The request for withdrawal of the dossiers and re-submission is part of the EMA procedural requirements linked to this re-inspection and will be considered by the EMA’s Committee of Medical Products for Human Use (CHMP), it